Lowering risk of 25 G surgery

Article

Although 25 G sutureless vitrectomy has increased in popularity, it is associated with postoperative complications including hypotony, choroidal detachment, and endophthalmitis. Richard Kaiser, MD, from the Retina Service of Wills Eye Institute, Philadelphia, noted that the 25 G procedure has a 12.4 times greater risk of endophthalmitis when compared with the 20 G procedure.

Although 25 G sutureless vitrectomy has increased in popularity, it is associated with postoperative complications including hypotony, choroidal detachment, and endophthalmitis. Richard Kaiser, MD, from the Retina Service of Wills Eye Institute, Philadelphia, noted that the 25 G procedure has a 12.4 times greater risk of endophthalmitis when compared with the 20 G procedure.

In light of this, the Microsurgical Safety Task Force has disseminated guidelines aiming to reduce the high rate of endophthalmitis associated with 25 G vitrectomy. The measures suggested included: rinsing the lidocaine gel from the ocular surface to allow direct contact of povidone iodine 10% with the conjunctiva; displace the conjunctiva with a cotton tip rather than instruments such as forceps or a caliper, which may cause microholes; use angled, rather than straight-entry, incisions and a tapered exit, to facilitate wound closure and maintenance of preop IOP level; rather than filling the eye with fluid, conduct an air-fluid exchange; and maintain a low threshold for placing a suture at the end of the case.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.